Study shows Byetta reduces cardiovascular risk factors in type 2 diabetics
Byetta also showed sustained improvements in blood glucose control and progressive weight loss through three and a half years of therapy. People with type 2 diabetes are at
Mereo BioPharma and Zydus Lifesciences subsidiary Sentynl Therapeutics have signed an option and licence agreement related to the US commercial and worldwide manufacturing rights to alvelestat, a potential oral treatment for Alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).